SG3 Management’s Aldeyra Therapeutics ALDX Stock Holding History

SG3 Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,000	Closed	-$61K	–	1016
2021 Q3	$61K	Buy	+7,000	New	+$64.2K	﹤0.01%	902

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SG3 Management's ALDX Position: Q4 2021 in Review

SG3 Management sold out of Aldeyra Therapeutics (ALDX) in Q4 2021, closing a stake of 7,000 shares — an estimated $61K sold.

SG3 Management first reported a position in ALDX in Q3 2021 and held it in 1 quarter. The position peaked at $61K in Q3 2021. 115 funds tracked by Wall St. Rank hold ALDX as of Q4 2021.

SG3 Management reported no remaining Aldeyra Therapeutics position as of Q4 2021 after selling out during the quarter.
SG3 Management sold 7,000 Aldeyra Therapeutics shares in Q4 2021, an estimated $61K.
SG3 Management first reported a position in Aldeyra Therapeutics in Q3 2021 and held it in 1 quarter.
SG3 Management's Aldeyra Therapeutics position peaked at $61K in Q3 2021.
115 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.